In a cohort of Chinese patients, researchers found that routine blood and urine test results may be useful for predicting the probabilities of the risk for hepatocellular carcinoma, according to a poster presentation at the European Society for Medical Oncology’s European Cancer Congress.
“Today, liver cancer is very difficult to diagnosis, for most of the patients, liver transplantation is their only hope,” the researchers wrote. “Early prediction of liver cancer could save millions [of] people in the world.”
Researchers in China analyzed data of 460,627 Chinese people, including 14,450 patients with HCC and 446,177 without HCC. Forty-eight data points were used for the analysis, including demographic data, complete blood count (CBC), complete metabolic panel (CMP) and lipids and urinalysis. The researchers also used an analysis of covariance, logistic analysis and discriminant analysis to identify the significant factors for predicting HCC and to build the risk prediction model, according to the abstract.
The analysis showed that CBC, CMP, lipids and urinalysis data can differentiate between patients with HCC from those without HCC. The data also showed that it could be used to build lung cancer risk prediction models, with an accuracy of over 95%.
“The top parameters selected by the prediction model were gamma glutamyl transpeptidase, percentage of monocytes, absolute differential counts of monocytes, urobilinogen, red cell distribution width and apolipoprotein B,” the researchers wrote.
In 2014, a total of 113,557 people, including 3,480 patients with HCC and 110,077 without HCC, were verified by the prediction model. The accuracy of the verification was also over 95%, according to the abstract.
The researchers concluded: “This research shows that the routine blood and urine test results can be used to predict the probabilities of the early liver cancer risk and the accuracy of the prediction is over 95%. The research would provide an effective, convenient and economical method in the early liver cancer prevention and help both patients and doctors monitor early liver cancer risk.”
Tao LW, et al. Abstract 1116. Presented at: European Cancer Congress; Sept. 25-29, 2015; Vienna.
Disclosures: The researchers report no relevant financial disclosures.